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Diabetes mellitus (DM) is a worldwide growing disease and represents a huge social and healthcare problem owing to the
burden of its complications. Micro- and macrovascular diabetic complications arise from excess damage through well-known
biochemical pathways. Interestingly, microangiopathy hits the bone marrow (BM) microenvironment with features similar to
retinopathy,nephropathyandneuropathy.TheBMrepresentsareservoirofprogenitorcellsformultiplelineages,notlimitedtothe
hematopoieticsystemandincludingendothelialcells,smoothmusclecells,cardiomyocytes,andosteogeniccells.Allthesemultiple
progenitor cell lineages are profoundly altered in the setting of diabetes in humans and animal models. Reduction of endothelial
progenitor cells (EPCs) along with excess smooth muscle progenitor (SMP) and osteoprogenitor cells creates an imbalance that
promote the development of micro- and macroangiopathy. Finally, an excess generation of BM-derived fusogenic cells has been
found to contribute to diabetic complications in animal models. Taken together, a growing amount of literature attributes to
circulating progenitor cells a multi-faceted role in the pathophysiology of DM, setting a novel scenario that puts BM and the blood
at the centre of the stage.
1. The Burden of DiabeticComplications
Diabetes mellitus (DM) has reached a worldwide grow-
ing epidemic diﬀusion. DM is associated with a signiﬁ-
cantly reduced quality of life and represents an important
health and social problem. Most importantly, DM leads to
severe complications in many organs and tissues through
the induction of microangiopathy and macroangiopathy.
Hyperglycemia-induced biochemical abnormalities, such as
overactivation of PKC and MAPK, excess ﬂux through the
exosamineandpolyolpathways,andproductionofadvanced
glycation end-products (AGEs), all stem from the high
concentrationofreactiveoxygenspeciesinducedbytheover-
ﬂowing mitochondrial respiratory chain [1]. These damage
pathways induce profound changes in vascular endothelial
andsmoothmusclecellsandsubsequentmodiﬁcationsofthe
extracellular matrix (ECM). DM increases 2-3-fold the risk
of cardiovascular disease (CVD), owing to the widespread
endothelial dysfunction, which is considered the ﬁrst step
in the atherogenetic process [2, 3]. Atherosclerotic vascular
disease in DM is aggressive, multifocal, distal and develops
earlier than in non-DM subjects. Importantly, other cardio-
vascular risk factors that typical associate with DM, such as
hypertension, obesity and dyslipidemia, concur to the accel-
erated risk of CVD. Microvascular complications, including
retinopathy, nephropathy, and neuropathy, develop as a
consequence of structural and functional damage to the
microcirculation of target organs. Typical morphological
features include thickening of the basement membrane, loss
of pericyte coverage, capillary rarefaction, excess deposition
of stiﬀ EMC components leading to reduced perfusion,
atrophic changes, and ﬁbrosis. All these morphological
features are reﬂected by organ dysfunctions, including visual
loss, impaired glomerular ﬁltration or tubular resorption,
reduced nerve conduction velocity. Importantly, organs that
are less commonly recognized among the targets of diabetic
microangiopathy are the myocardium, the lung, and the
bone marrow (BM).2 Experimental Diabetes Research
2.The PlasticityofCirculating
Progenitor Cells
In the adult organism, the BM represents the privileged
site of hematopoiesis and the reservoir of stem/progenitor
cells. In the last decades, it has been recognized that the
BM harbours small subsets of progenitor cells for multiple
cell lineages, not limited to the hematopoietic system [4, 5].
These cells can leave the BM upon appropriate stimulation
and migrate in peripheral organs through the bloodstream.
The prevailing concept is that immature cells in the BM
niche retain plasticity and can undergo a multilineage dif-
ferentiation, recapitulating some developmental steps taking
place in embryonic stem cells. The best known form of this
phenomenon is endothelial diﬀerentiation of BM-derived
cells, which gives rise to endothelial progenitor cells (EPCs)
[6]. Cell-tracking experiments using BM chimeric mice
expressing the green ﬂuorescent protein (GFP) or other
reporters found that BM-derived cells can repopulate several
organs and tissues, diﬀerentiating into multiple phenotypes
[7–9]. Similarly, the study of rare cases of human sex-
mismatched transplantation allowed to follow the fate of
BM-derived cells by looking at the signal of the sex chromo-
somes and showed repopulation of the myocardium, lungs,
kidney, and gastrointestinal tract by donor-derived cells [10–
13]. It should be noted that not all studies unequivocally
conﬁrm the ability of BM-derived cells to contribute to
peripheral cellular phenotypes diﬀerent from hematopoietic
cells [14, 15]. This discrepancy may depend upon the use
of diﬀerent cell tracking methods, imaging techniques, and
disease models.
3.EndothelialProgenitorCells
EPCs are immature BM-derived cells which undergo diﬀer-
entiation into endothelial cells and participate in endothelial
repair and neoangiogenesis [6]. EPCs are commonly deﬁned
and enumerated by ﬂow cytometry based on the co-
expression of stemness antigens (e.g., CD34 and/or CD133)
and endothelial markers (e.g., KDR). EPCs can also be
isolated from circulating mononuclear cells using disparate
cultureprotocolsyieldingheterogeneouscelltypes(reviewed
elsewhere[16]).Brieﬂy,itshouldbetakenintoaccountthata
net separation between EPCs and hematopoietic cells, either
progenitor or myeloid lineage-committed cells, is not always
possible. As a result, several cultured EPC phenotypes retain
overlapping features with the hematopoietic system [17].
EPCs can be mobilized from the BM into the peripheral
blood in response to many stimuli including tissue ischemia,
cytokines, and growth factors [18]. Once in the bloodstream,
EPCs home speciﬁcally to sites of vascular damage to repair
the disrupted endothelium and to provide pro-angiogenic
stimuli in an attempt to restore blood ﬂow and counter
shortage of oxygen and nutrients [19]. With these two
seminal functions, it is easy to understand how EPCs act
as an integrated component of the cardiovascular system,
whichissubjectedtopathologicalchangesandisalsoatarget
of therapy. Importantly, EPCs are profoundly altered in the
setting of type 1 and type 2 DM [20]. Several antigenic EPC
phenotypes (e.g., CD34+KDR+) are profoundly reduced
in the blood of type 2 diabetic patients compared to
controls, independently of concomitant risk factors [21].
Pauperization of EPCs in diabetes is thought to explain, at
least in part, the high CVD risk associated with DM, as
patients would be less able to repair the endothelial injury
and to counter ischemia with neoangiogenesis. Indeed,
there is a close negative correlation between the severity of
vascular disease and the level of circulating EPCs in diabetic
patients [22]. The reduction of EPCs may also intervene
as a pathogenic factor in microangiopathy, as clinically
signiﬁcant correlations have been found in the setting of
retinopathy, nephropathy, and wound healing [23–25]. Not
only EPCs are reduced in the bloodstream of diabetic
patients, but they also show functional defects, such as
impaired adhesion, proliferation, andtubulogenesis [22,26].
These data support the notion that an altered EPC biology in
DM compromises the ability to counter the excess damage
caused by hyperglycemia and the associated biochemical
abnormalities [27]. Besides a pathophysiological role in
diabetic complications, the level of circulating EPCs may
also represent a biomarker of future risk, as progenitor
cell counts independently predict the occurrence of adverse
cardiovasculareventsindiﬀerentcohortsofpatients[28,29].
4. Smooth Muscle Progenitor Cells
Circulating SMPs were originally identiﬁed by studies in
which mice were transplanted with genetically labelled BM
and, after vascular injury, it was found that a quote of
cells within the neointima coexpressed BM-tracing markers
and alpha-SMA [7, 30, 31]. While these ﬁndings were not
conﬁrmed by other investigators [32, 33], data also accu-
mulated on the possibility to isolate SMPs from peripheral
blood mononuclear cells using diﬀerent culture protocols
(reviewed in [34] ) .T h ee x a c tp h e n o t y p eo fS M P si su n c l e a r
and residual overlapping with the hematopoietic system
(such as CD14 and/or CD45 expression) may occur as for
EPCs. EPCs and SMPs may also share a common ancestor
and cells may undergo shift from and back each phenotype
in vitro and in vivo [35]. SMPs can be obtained from
the CD34+ population and/or from the CX3CR1+ myeloid
population [36, 37]. The existence of SMP has important
implications for tissue engineering, as SM cells are necessary
to create vascular grafts, but also holds negative implications
for vascular disease, in which SM cells may play detrimental
roles. In the setting of DM, SM cell function and phenotype
are altered and some cells are shifted from a contracting
phenotype to a secreting phenotype [38]. Nguyen et al. have
reported that PBMC from diabetic patients as compared to
controls, when cultured in conditions that foster SM cell
growth, gives rise to a higher number of SM-like progenitor
cells expressing both contractile and ﬁbrogenous markers
[39]. These ﬁndings were suggestive of the fact that circu-
lating progenitors in DM are shifted from the generation
of an endothelial phenotype to a SM phenotype. As it
has been shown that BM-derived cells home to sites ofExperimental Diabetes Research 3
glomerular damage [40], these cells may intervene in the
settingofdiabeticmicrovascularcomplications,contributing
for instance in the progression of diabetic nephropathy.
Consistently with these ﬁndings, In a mouse model of
type 1 diabetes, Westerweel et al. found an accelerated
generation of SMP from blood cells, probably driven by
the TGF-beta signalling. In addition, GFP+ BM-derived
cells coexpressing SM cell markers were recruited at sites of
neointima formation after cuﬀ arterial damage, which was
increased in diabetic animals [41].
Pericyte progenitor cells (PPCs) represent a phenotype
closely related to SMPs. They are typically deﬁned by ex-
pression of pericyte markers, such as PGDFRbeta and/or
NG2. PPCs can be isolated from mature blood vessels and
show potent vasoregenerative potential [42], just as per-
icyte govern vascular stability. Circulating PPCs have been
identiﬁed, although their origin is not clear [43]. We have
reported that PPCs are increased in diabetic patients with
microangiopathy after improvement of glucose control [44].
The clinical signiﬁcance of this ﬁnding remains to be
elucidated. Speculatively, increased vasoprotective PPCs may
represent a beneﬁcial eﬀect of glucose control that translates
into improved outcomes. Alternatively, the surge in PPC
level may represent a consequence of microvascular lesion
regression or even progression, as microangiopathy can
occasionally worsen after rapid glucose control.
5. CardiomyocyteProgenitor Cells
Early studies using GFP BM chimeric mice were able to
detect an extensive repopulation of the infarcted myo-
cardium by BM-derived cells, with initial evidence of
transdiﬀerentiation of homed cells into cardiomyocytes [8,
45]. In humans, a proof of concept of this biological
phenomenon has been provided in sex mismatched heart
transplants, showing high level of cardiac chimerism caused
by the migration of primitive cells from the recipient to
the grafted heart [10, 46, 47]. The phenotype and kinetics
of BM-derived circulating cardiomyocyte progenitor cells
(CPCs) have been subsequently investigated. For instance,
Wojakowski et al. found that myocardial infarction induces
the BM to release CD34/CXCR4+, CD34/CD117+, and c-
Met+ progenitor cells, which express the cardiac genes
GATA4, MEF2C, Nkx2.5/Csx [48]. The extent to which these
cells engraft into the infarcted heart was not determined
and the true quantitative contribution of BM-derived cells
in myocardial remodelling after injury has been questioned
[49, 50]. An important issue is that EPCs themselves have
the potential to transdiﬀerentiate into cardiomyocytes in
vitro, when co-cultured with neonatal rat heart cells [51].
Interestingly, this phenomenon is impaired in patients with
coronary artery disease and can be restored by statin therapy
[52]. Whether cardiomyocyte diﬀerentiation of circulating
p r o g e n i t o r si sa ﬀected by diabetes remains to be established.
6. Osteoprogenitor Cells
Ectopic calciﬁcation is a hallmark feature of diabetic vascu-
lopathy [53]. Calciﬁcation can develop in the medial layer or
in the neointima of atherosclerotic plaques. Medial calciﬁed
arteriosclerosis leads to arterial stiﬀening and raises blood
pressure, while neointimal calciﬁcation can destabilize the
plaque and lead to rupture or hemorrhage. The mechanisms
driving vascular calciﬁcation are incompletely understood,
ranging from ion imbalance, loss of inhibitors, and cellular
alterations [54]. The type of vascular cells giving origin to
calcifying cells is also unclear, with SM cells, pericytes, and
advential progenitor cells possibly being involved. Recent
data show that circulating calcifying cells (osteoprogenitor
cells, OPCs) contribute to intraplaque calciﬁcation [55],
while a role for BM-derived cells in medial calciﬁcation has
not been substantiated so far [56]. OPCs may originate from
theBMhematopoieticormesenchymalcompartments.Ithas
been shown that CD34+ cells and EPCs can express bone-
related proteins, such as osteocalcin (OC) and bone alkaline
phosphatase (BAP) and develop a tendency to form calciﬁed
nodules in vitro and when using in vivo assays [57]. These
osteogenic EPCs, or OPCs, are increased in patients with
coronaryarterydisease,anddatainhumanssuggestthatthey
are recruited from the bloodstream to the diseased coronary
arteries [57, 58]. Expression of OC on EPCs correlates with
arterial stiﬀness in humans [59], lending support to the
hypothesis that OPG participates in arterial calciﬁcation. In
diabetic patients with coronary artery disease, CD34+ cells
show a phenotypic shift from endothelial commitment to
a procalciﬁc phenotype, as evidenced from the excess OC
expression over KDR [60]. In cultured monocytic EPCs, this
phenomenon may be attributable to inﬂammatory stimuli,
as it can be recapitulated by LPS [60]. In addition, we have
recently identiﬁed a subpopulation of circulating monocytes
expressing OC and BAP, called myeloid calcifying cells
(MCCs), that are increased in the BM, peripheral blood, and
atherosclerotic lesions of diabetic patients compared to con-
trols [61]. MCCs represent one aspect of monocyte plasticity
and a novel indicator of deranged monocyte biology in the
setting of DM. Finally, OPCs may also derive from the BM
mesenchymal compartment and can be mobilized into the
bloodstreaminresponsetobonefractures[62].Thecomplex
epidemiologic and pathophysiologic relationships between
boneandvasculardiseasesuggestthatOPCsmaybeinvolved
in the regulation of the bone vascular axis [63], through
yet unidentiﬁed mechanisms. In support of this, osteogenic
EPCs appear to be increased also in osteoporotic women
[64].
7. Proinsulin-ExpressingCells
A few years ago, while studying gene therapy in strep-
tozotocin (STZ) diabetic mice, a group of investigators
detected expression of the insulin gene in several organs
and tissues outside the endocrine pancreas [65]. Then, they
identiﬁed proinsulin- (PI-) expressing cells that appear in
animals after induction of hyperglycemia. These cells derive
from the BM, resemble cells of the monocyte/macrophage
lineageand display a proinﬂammatory phenotype, as evi-
denced by the expression of TNF-alpha. When looking at
the distribution of the PI-expressing BM-derived cells (PI-


















































Figure 1: The multifaceted contribution of circulating progenitor cells in diabetic complications. Diﬀerent lineage-committed progenitor
cells are altered in the setting of diabetes and contribute to the development of diabetic complications. Grey arrows indicate the eﬀects of
diabetes of number and function of the various bone-marrow-derived cell subtypes.
these cells in multiple tissues and organs [66]. Importantly,
PI-BMDCs appear to have enhanced fusogenic properties, at
least in part mediated through the diabetes-speciﬁc PARP-1
pathway [67]. Fusion of PI-BMDCs with resident cells has
been shown to contribute to diabetic complications [68].
For instance, fusion of hematopoietic cells with peripheral
neurons impairs nerve function in a diabetic mouse model
[69, 70]. Additionally, fusion of PI-BMDCs with renal
tubule cells is believed to contribute to the development
and/or progression of diabetic nephropathy, as the resulting
polyploid cells are proinﬂammatory and interfere with
normal tubule function [71]. The fusogenic properties of
these cells are abolished when mice are transplanted with
BM cells from PARP−/− donors [67]. Interestingly, an
excess generation of these proinﬂammatory PI-expressing
myeloid cells after development of diabetes may contribute
to virtually all diabetic complications, by means of fusion
with resident cells. This is an entirely new mechanism of
action that link BM cells to distant target organs. Whether
or not this mechanism is active also in humans needs to be
addressed.
8. The DiabeticBone Marrow
The profound alterations of all these circulating progenitors
intuitively led investigators to hypothesize a BM defect
associated with DM. In 2006, we ﬁrst reported that BM
mobilization of progenitor cells is impaired in diabetic
animals compared to controls after stimulation by ischemia
or exogenous mobilizing agents (G-CSF and SCF) [72].
The postischemic mobilization was defective in DM because
ischemia was unable to upregulate the hypoxia sensing
system HIF-1alpha and its downstream targets (such as SDF-
1alpha), which signal the BM for the need of vasoregen-
erative progenitor cells, like EPCs. This pathway has been
subsequently conﬁrmed by others and defects of the HIF-
1alpha pathway in DM have been better elucidated [73, 74].
On the other hand, to explain the impaired progenitor
cell mobilization after direct BM stimulation, an intrinsic
BM defect had to be postulated. Recently, Oikawa et al.
have shown that DM induced BM microangiopathy with
morphological features similar to other typical diabetic
microvascular complications, including basement mem-
brane thickening, capillary rarefaction and apoptosis [75].
As a functional consequence stem cell niche characteristics
were altered, thus potentially aﬀecting the BM response to
mobilizing agents. Busik et al. have found that DM impairs
autonomic bone marrow innervation, which is critical for
G-CSF induced mobilization of stem/progenitor cells. This
BM neuropathy, in turn, compromised the extent and
timing of progenitor cell release, an event that preceded
the development of distant vascular complications [76]. The
early onset of bone marrow defect in the natural history of
diabetes is also suggested by a study showing that CD34+
cells start to decline in prediabetes and show a ﬁrst nadir
in newly diagnosed type 2 DM [77]. More recently, Ferraro
et al. showed that STZ diabetes in mice interrupts the
dynamic anatomy of the BM stem cell niche suggesting a
defect in the activation of the sympathetic nervous system
with consequent impaired SDF-1alpha regulation. As a
clinically relevant counterpart, they show in a retrospective
case series that G-CSF stem cell mobilization in patients
undergoing autologous transplantation is impaired in the
presence of diabetes or hyperglycemia [78]. This issue is
being explored in an ongoing prospective clinical trialExperimental Diabetes Research 5
in diabetic and non diabetic patients (NCT01102699), as
a proof-of-concept for the so-called diabetic stem cell
“mobilopathy” [79]. However, it is fascinating that complex
niche dysfunction in DM may not only impair progenitor
cell mobilization, but also aﬀect diﬀerentiation of progenitor
cells, with defective generation of EPCs and CPCs and
excess production of SMPs, OPCs and PI-BMDCs that exert
detrimental eﬀects on diabetic complications [80].
9. Concluding Remarks
The studies summarized so far currently attribute to circu-
lating progenitors for multiple cell lineages important roles
in the pathogenesis of diabetic complications. Progenitor
cells typically originate from the BM and intrinsic BM
alterations in DM begin to be characterized. Thus, the
emerging scenario put the BM in the centre of a new
pathophysiological model of diabetic complications, as a
link between distant and disparate target organs (Figure 1).
Importantly, stem cell failure is typically associated with
aging and it is worth to note that, owing to the burden
of complications, DM is considered a disease of accelerated
aging [81].
At least some of the progenitor cell dysfunction found in
DMarereversible[82–84].Forinstance,glucosecontrolwith
insulin therapy has been shown to increase EPCs [85] while
normalization of glucosemetabolism byislet transplantation
in type 1 diabetes reversed EPC defects [86]. In addition,
inhibition of DPP-4 with sitagliptin increased EPCs in 4
weeks in type 2 diabetic patients, possibly through an eﬀect
on SDF-1alpha [87]. Finally, the discovery of progenitor cell
reduction in diabetes represents the rationale for devising
cell-based therapeutic strategies [88], which show promising
results for both coronary and peripheral vascular disease
[89, 90].
Despite these data, several aspects of progenitor cells
biology in DM still need to be extensively investigated.
Among all, the monocyte plasticity and its deranged polar-
ization [91], which is thought to account for unbalanced
EPC, SMP, MCC and PI-BMDC generation, deserve a special
attention.
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